Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Part of paid clinical trials in Tamarac, Florida.

Sponsor
Rigel Pharmaceuticals
Study ID
NCT04904276
Status
Terminated

Conditions

  • ITP
  • Immune Thrombocytopenia

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Evaluate patient characteristics, treatment patterns, clinical outcomes and safety of fostamatinib as second-line therapy in real-world clinical practice, for the treatment of ITP in adult patients who have an insufficient response to prior therapy (steroids ± immunoglobulins).

Key Dates

Start date
May 18, 2021
Status verified
Mar 2024
Primary completion
Nov 17, 2022
Completion
Nov 17, 2022

Study Design

Enrollment
16 participants (actual)

Arms

  • Arm: Initiating treatment with fostamatinib as second-line therapy
  • Arm: Treated with fostamatinib for at least 12 weeks as second-line therapy

Primary Outcome Measure

Fostamatinib dosing [ Time Frame: 12-month observation period ]

Locations (14)

FacilityCityStateZIPSite coordinators
Advanced ResearchTamaracFlorida33321-
Simmons Cancer Institute at Southern Illinois UniversitySpringfieldIllinois62702-
University of Kansas Medical CenterKansas CityKansas66160-
Saint Agnes HospitalBaltimoreMaryland21229-
The Center for Cancer and Blood DisordersBethesdaMaryland20817-
Maryland Oncology Hematology, P.AClintonMaryland20735-
Maryland Oncology Hematology, P.AColumbiaMaryland21044-
Maryland Oncology Hematology, P.ARockvilleMaryland20850-
Maryland Oncology Hematology, P.ASilver SpringMaryland20904-
Boston Medical CenterBostonMassachusetts02118-
Washington UniversitySt LouisMissouri63130-
Regional Cancer Care Associates, LLCLittle SilverNew Jersey07739-
New York Medical CollegeValhallaNew York10595-
New York Medical College Westchester Medical CenterValhallaNew York10532-

Find similar trials in Tamarac, FL

By research site
Advanced Research· Tamarac, FLSimmons Cancer Institute at Southern Illinois University· Springfield, ILUniversity of Kansas Medical Center· Kansas City, KSSaint Agnes Hospital· Baltimore, MDThe Center for Cancer and Blood Disorders· Bethesda, MDMaryland Oncology Hematology, P.A· Clinton, MD

Related Studies